Projet INTEGRATE (Horizon 2020, appel à projets 2014)
Action : Doctoral Networks
Panel : Life Sciences
Statut du projet : CLOSED

Antimicrobial resistance is posing a continuously-rising threat to global health. Indeed, one key recommendation from the recent “Action plan against the rising threats from Antimicrobial Resistance” report (submitted by the Commission to the European Parliament and Council (15.11.2011)) is the development of effective antimicrobials or alternatives for treatment of human and animal infections. The INTEGRATE project is a direct response to this. We have assembled a team of 10 beneficiaries from eight EU member states, encompassing both academic and non-academic sectors and different disciplines, to form a consortium committed to training Early Stage Researchers (ESRs) in the discovery and preclinical validation of novel Gram-negative antibacterial agents and antibacterial targets. The principle aim of the consortium is to provide a training platform where students are exposed to every aspect of the antimicrobial discovery process, ranging from target identification and validation, through organic synthesis, in silico design and compound screening, to mode-of-action and possible resistance mechanisms. This exposure will be accomplished through a concrete secondment plan, coupled with a series of high-level consortium-wide training events and networking programmes. Our intention is to reverse the current fragmentation of approaches towards antibacterial discovery through mutual cooperation. The INTEGRATE training framework is built on an innovative research project aimed at targeting important but non-essential gene products as an effective means of reducing bacterial fitness, thereby facilitating clearance of the pathogen by the host immune system. To achieve this, the individual work programmes have been designed to seamlessly inter-mesh contributions from the fields of in silico design, organic synthesis, molecular biology and biochemistry, and the very latest in vitro and in vivo screening technologies.

Mots clés : antibacterials, gram negative, drug discovery, targets

Participants :
- Taros chemicals gmbh & co kg (Allemagne) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 249216.48 €
- University of Helsinki (Finlande) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 269145.36 €
- University of Cambridge (Royaume-Uni) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 273287.88 €
- Fraunhofer Society (Allemagne) — Partner, beneficiary, Recherche, subvention : 249216.48 €
- CSC - IT Center for Science (Finland) (Finlande) — Partner, organization partner, Autres, subvention : 0.0 €
- University of Antwerp (Belgique) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 250560.0 €
- Tampere University (Finlande) — Partner, organization partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- University of Parma (Italie) — Coordinator, beneficiary, Enseignement supérieur ou secondaire, subvention : 516122.64 €
- University of Eastern Finland (Finlande) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 269145.36 €
- University of Ljubljana (Slovénie) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 234997.56 €
- Finnish patent office and registration (Finlande) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Latvian Academy of Sciences (Lettonie) — Partner, beneficiary, Recherche, subvention : 223577.64 €
- Matera, lda (Portugal) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Aptuit (Italy) (Italie) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 258061.32 €